Koers Nymox Pharmaceutical Corporation
Aandelen
NYMXF
BSP733981026
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,3498 USD | +7,65% | +16,60% | -40,71% |
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 29,51 mln. 27,68 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -12 mln. -11,26 mln. | Nettowinst (verlies) 2022 | -6 mln. -5,63 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 439K 412K | Nettoliquiditeiten 2022 | 1,23 mln. 1,15 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-8,5
x | K/w-verhouding 2022 |
-4,39
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 57,95% |
1 dag | +7,65% | ||
1 week | +16,60% | ||
Lopende maand | -12,55% | ||
1 maand | -0,06% | ||
3 maanden | -22,23% | ||
6 maanden | -65,02% | ||
Lopend jaar | -40,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Patrick Doody
BRD | Director/Board Member | - | 12-07-23 |
Director/Board Member | - | 21-03-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 08-06-06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 30-05-95 |
Director/Board Member | 88 | 01-07-15 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
30-04-24 | 0,3498 | +7,65% | 22 965 |
29-04-24 | 0,325 | +8,32% | 15 531 |
26-04-24 | 0,3 | -.--% | 3 833 |
25-04-24 | 0,3 | -6,25% | 419 |
24-04-24 | 0,32 | +6,67% | 1 752 |
uitgestelde koers OTC Markets, 30 april 2024 om 20:17 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-40,71% | 30,34 mln. | |
+0,17% | 42,86 mld. | |
+10,92% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,23% | 25,15 mld. | |
-24,79% | 18,63 mld. | |
+26,69% | 12,37 mld. | |
-3,13% | 11,92 mld. | |
+6,57% | 11,21 mld. |